Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast

Bibliography

• AMERICAN THORACICSOCIETY: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: ATS statement. Am. J. Respir. Crit. Care Med. (1995) 152:S77-S120.
   Web of Science ®Google Scholar
• VIGNOLA AM: PDE4 inhibitors in COPD – a more selective approach to treatment. Respir. Med. (2004) 98:495-503.
   Google Scholar
• CAZZOLA M, DONNER CF, MATERA MG: Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax (1999) 54:730-736.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Therapy of chronic obstructive pulmonary disease. Pharmacol. Ther. (2003) 97:87-94.
   Web of Science ®Google Scholar
• PAUWELS RA, BUIST AS, CALVERLEY PM, JENKINS CR, HURD SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. (2001) 163:1256-1276.
   Google Scholar
• TORPHY TJ, ZHOU H-L, CIESLINSKI LB: Elevation of cyclic AMP content in U937 cells increases the activity of the cyclic AMP-specific phosphodiesterase. J. Pharmacol. Exp. Ther. (1992) 263:1195-1204.
   Google Scholar
• TORPHY TJ, DE WOLF WE, GREEN DW, LIVI GP: Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions (1993) 43S:51-71.
   Google Scholar
• SCHMIDT D, SZELENYI I, POPPE H, MAGNUSSEN H, RABE KF: Effect of a novel PDE4 inhibitor AWD 12-281 on allergen-induced contractions in passively sensitized human airways. Am. J. Respir. Crit. Care Med. (1999) 159:A854 (Supplement).
   Google Scholar
• COMPTON CH, GUBB J, NIEMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet (2001) 358:265-270.
   PubMed Web of Science ®Google Scholar
• LEICHTL S, SYED J, BREDENBRÖKER D, RATHGEB F, WURST W: Efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 165:A229.
   Google Scholar
• LE JEUNE IR, SHEPHERD M, VAN HEEKE G, HOUSLAY MD, HALL IP: cAMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells: identification and characterization of a novel PDE4D5 promoter. J. Biol. Chem. (2002) 277:35980-35989.
   PubMed Web of Science ®Google Scholar
• BRAUNSTAHL GJ, FOKKENS WJ, OVERBECK SE, KLEINJAN A, HOOGSTEDEN HC, PRINS JB: Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin. Exp. Allergy (2003) 33:579-587.
   Google Scholar
• WENZEL SE, BALZAR S, CUNDALL M, CHU HW: Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation and wound repair. J. Allergy Clin. Immunol. (2003) 111:1345-1352.
   Google Scholar
• HUANG Z, DUCHARME Y, MacDONALD D, ROBICHAUD A: The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. (2001) 5:432-438.
   Web of Science ®Google Scholar
• GIEMBYCZ MA: Phosphodiesterase-4- selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc. Am. Thorac Soc. (2005) 2:326-333.
   Google Scholar
• STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121:192S-196S.
   PubMed Web of Science ®Google Scholar
• TIMMER W, LECLERC V, BIRRAUX G: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol. (2002) 42:297-303.
   Google Scholar
• PROFITA M, CHIAPPARA G, MIRABELLA F et al.: Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax (2003) 58:573-579.
   PubMed Web of Science ®Google Scholar
• CONTI M, JIN SLC: The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. (2000) 63:1-38.
   Web of Science ®Google Scholar
• SODERLING SH, BEAVO JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. (2000) 12:174-179.
   Web of Science ®Google Scholar
• ARIGA M, NEITZERT B, NAKAE S et al.: Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. (2004) 173:7531-7538.
   Google Scholar
• HOUSLAY MD, ADAMS DR: PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. (2003) 370:1-18.
   Google Scholar
• GIEMBYCZ MA: Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2001) 10(7):1361-1379.
   Google Scholar
• MANNING CD, BURMAN M, CHRISTENSEN SB et al.: Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. (1999) 128:1393-1398.
   Web of Science ®Google Scholar
• CONTI M, RICHTER W, MEHATS C, LIVERA G, PARK JY, JIN C: Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. (2003) 278:5493-5496.
   PubMed Web of Science ®Google Scholar
• HANSEN G, JIN S, UMETSU DT, CONTI M: Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. USA (2000) 97:6751-6756.
   Google Scholar
• JIN CL, CONTI M: Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS activated TNF-α response. Proc. Natl. Acad. Sci. USA (2002) 99:7628-7633.
   Google Scholar
• OGER S, MEHATS C, BARNETTE MS, FERRE F, CABROL D, LEROY MJ: Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Biol. Reprod. (2004) 70:458-464.
   Google Scholar
• JACOB C, LEPORT M, SZILAGYI C, ALLEN JM, BERTRAND C, LAGENTE V: DMSO-treated HL60 cells: a model of neutrophil-like cells mainly expressing PDE4B subtype. Int. Immunopharmacol. (2002) 2:1647-1656.
   Google Scholar
• BROWN WM: Cilomilast. Curr. Opin. Investig. Drugs (2005) 6:545-558.
   Web of Science ®Google Scholar
• SOUNESS JE, RAO S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal. (1997) 9:227-236.
   PubMed Web of Science ®Google Scholar
• LIU S, LALIBERTE F, BOBECHKO B et al.: Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry (2001) 40:10179-10186.
   PubMed Web of Science ®Google Scholar
• JACOBITZ S, McLAUGHLIN MM, LIVI GP, BURMAN M, TORPHY TJ: Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. (1996) 50:891-899.
   Google Scholar
• ASHTON MJ, COOK DC, FENTON G et al: Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem. (1994) 37:1696-1703.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, GRIFFIN M, MASLEN C et al.: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br. J. Pharmacol. (1996) 118:649-658.
   Web of Science ®Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al.: SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor suppresses activities of several immune and inflammatory cells. Am. J. Resp. Crit. Care Med. (1994) 149:A209.
   Google Scholar
• CHRISTENSEN SB, GUIDER AM, FORSTER CJ et al.: 1,4-Cylcohexane carboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. (1998) 41:821-835.
   PubMed Web of Science ®Google Scholar
• NICHOLSON CD, SHAHID M: Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes: their potential utility in the therapy of asthma. Pulm. Pharmacol. (1994) 7:1-17.
   PubMedGoogle Scholar
• CAVALLA D, FRITH R: Phosphodiesterase IV inhibitors: structural diversity and therapeutic potential in asthma. Curr. Med. Chem. (1995) 2:561-572.
   Web of Science ®Google Scholar
• PINTO IL, BUCKLE DR, READSHAW SA, SMITH DG: The selective inhibition of phosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. Bioorg. Med. Chem. Lett. (1993) 3:1743-1746.
   Web of Science ®Google Scholar
• CRESPO MI, PAGES L, VEGA A et al.: Design synthesis and biological activities of new thieno[3,2-d]pyrimidines as selective type 4 phosphodiesterase inhibitors. J. Med. Chem. (1988) 41:4021-4035.
   Google Scholar
• BUCKLE DR, ARCH JRS, CONNOLLY BJ et al.: Inhibition of cyclic nucleotide phosphodiesterase by derivativesof 1,2-bis(cyclo- propylmethyl)xanthine. J. Med. Chem. (1994) 37:476-485.
   PubMed Web of Science ®Google Scholar
• DOWN G, SIEDERER S, LIM S, DALEY-YATES P: Clinical pharmacology of cilomilast. Clin. Pharmacokinet. (2006) 45:217-233.
   Google Scholar
• ROBICHAUD A, STAMATIOU PB, JIN C et al.: Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioural correlate of emesis. J. Clin. Invest. (2002) 110:1045-1052.
   Google Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N, HELLEWELL PG: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. (1997) 18:164-171.
   Web of Science ®Google Scholar
• SOUNESS JE, ALDOUS D, SARGENT C: Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology (2000) 47(2-3):127-162.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, BARTUS JO, BURMAN M et al.: Association of the anti-inflammatory activity of phos-phodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. (1996) 51:949-956.
   Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. (1998) 157:351-370.
   Web of Science ®Google Scholar
• JACOB C, SZILAGYI C, ALLEN JM, BERTRAND C, LAGENTE V: Role of PDE4 in superoxide anion generation through p44/42 MAPK regulation: a cAMP and a PKA-independent mechanism. Br. J. Pharmacol. (2004) 143:257-268.
   Web of Science ®Google Scholar
• JIMENEZ JL, INIGUEZ MA, MUNOZ-FERNANDEZ MA, FRESNO M: Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal. (2004) 16:1363-1373.
   PubMed Web of Science ®Google Scholar
• HADDAD JJ, LAND SC, TARNOW-MORDI WO, ZEMBALA M, KOWALCZYK D, LAUTERBACH R: Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipo- polysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. (2002) 300:559-566.
   Google Scholar
• KWAK HJ, SONG JS, HEO JY, YANG SD, NAM JY, CHEON HG: Roflumilast inhibits lipo- polysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J. Pharmacol. Exp. Ther. (2005) 315:1188-1195.
   Google Scholar
• LAGENTE V, MOODLEY I, PERRIN S, MOTTIN G, JUNIEN JL: Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. (1994) 255:253-256.
   Web of Science ®Google Scholar
• LAGENTE V, PRUNIAUX MP, JUNIEN JL, MOODLEY I: Modulation of cytokine-induced eosinophil infiltration by phos-phodiesterase inhibitors. Am. J. Respir. Crit. Care Med. (1995) 151:1720-1724.
   Google Scholar
• ALVES AC, PIRES ALA, CRUZ HN et al.: Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur. J. Pharmacol. (1996) 312:89-96.
   Web of Science ®Google Scholar
• SILVA PMR, ALVES AC, SERRA MF et al.: Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phos-phodiesterase type 4 isoenzyme. Br. J. Pharmacol. (2001) 134:283-294.
   Web of Science ®Google Scholar
• TOWARD TJ, BROADLEY KJ: Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone. J. Pharmacol. Exp. Ther. (2001) 298:298-306.
   Google Scholar
• MIOTLA JM, TEIXEIRA MM, HELLEWELL PG: Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol. (1998) 18:411-420.
   Web of Science ®Google Scholar
• HOWELL RE, JENKINS LP, FIELDING LE, GRIMES D: Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in brown Norway rats. Pulm. Pharmacol. (1995) 8:83-89.
   PubMedGoogle Scholar
• LIPWORTH BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365(9454):167-175.
   PubMed Web of Science ®Google Scholar
• GRISWOLD DE, WEBB EF, BADGER AM et al.: SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. (1998) 287:705-711.
   Google Scholar
• COHAN VL, SHOWELL HJ, PAZOLES CJ et al.: In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J. Pharmacol. Exp. Ther. (1996) 278:1356-1361.
   Google Scholar
• JONES NA, BOSWELL-SMITH V, LEVER R, PAGE CP: The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm. Pharmacol. Ther. (2005) 18:93-101.
   Google Scholar
• GONÇALVES DE MORAES VL, SINGER M, VARGAFTIG BB, CHIGNARD M: Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. (1998) 123:631-636.
   Web of Science ®Google Scholar
• OUAGED M, MARTIN-CHOULY CAE, LEPORTIER C et al.: The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNF-α production in whole blood of COPD patients. Fund. Clin. Pharmacol. (2002) 16:369.
   Google Scholar
• LECLERC O, LAGENTE V, PLANQUOIS JM et al.: Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur. Respir. J. (2006) 27:1102-1109.
   Google Scholar
• CORBEL M, GERMAIN N, LANCHOU J et al.: The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-β release during acute lung injury in mice: the role of the balance between tumor necrosis factor-α and interleukin-10. J. Pharmacol. Exp. Ther. (2002) 301:258-265.
   Google Scholar
• JEFFREY PK: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax (1998) 53:129-136.
   PubMed Web of Science ®Google Scholar
• SEGURA-VALDEZ L, PARDO A, GAXIOLA M, UHAL BD, BECERRIL C, SELMAN M: Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest (2000) 117:684-694.
   PubMed Web of Science ®Google Scholar
• ZHU J, ANDERSON K, VLEISIDES T: The positive effect of cilomilast on lung function in patients with chronic obstructive pulmonary disease (COPD) is independent of patient smoking status. Eur. Respir. J. (2002) 20:620s.
   Google Scholar
• KOHYAMA T, LIU X, ZHU YK et al.: Phosphodiesterase 4 inhibitors cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastases. Am. J. Respir. Cell Mol. Biol. (2002) 27:487-494.
   Google Scholar
• MARTIN-CHOULY CA, ASTIER A, JACOB C, PRUNIAUX MP, BERTRAND C, LAGENTE V: Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. (2004) 75:823-840.
   Google Scholar
• MARTORANA PA, BEUME R, LUCATTELLI M, WOLLIN L, LUNGARELLA G: Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. (2005) 172:848-853.
   Google Scholar
• GAMBLE E, GROOTENDORST DC, BRIGHTLING CE et al.: Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 168:976-982.
   Google Scholar
• COMPTON CH, EDELSON JD, CEDAR E et al: Cilomast (Ariflo) 15 mg bid safety in a 6-month clinical trial program. Abs. Am. Thorac Soc. (2001):H52 (Poster).
   Google Scholar
• JEFFERY P: Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm. Pharmacol. Ther. (2005) 18:9-17.
   Google Scholar
• GROOTENDORST DC, GAUW SA, BAAN R et al.: Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm. Pharmacol. Ther. (2003) 16:115-120.
   Google Scholar
• EDELSON JD, COMPTON C, NIEMAN R et al.: Cilomilast (Ariflo) improves health status in patients with COPD: results of a 6-month trial. Abs. Am. Thorac Soc. (2001):302 (Poster).
   Google Scholar
• EDELSON JD, COMPTON C, NIEMAN R: Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: results of a 6-month trial. Am. J. Respir. Crit. Care Med. (2001) 163:A277.
   Web of Science ®Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al.: SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. (1998) 284:420-426.
   Google Scholar
• MURDOCH RD, COWLEY H, UPWARD J, WEBBER D: The safety and tolerability of Ariflo™ (SB 207499), a novel selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Am. J. Respir. Crit. Care Med. (1998) 157:A409 (Supplement).
   Web of Science ®Google Scholar
• SLIM RM, SONG Y, ALBASSAM M, DETHLOFF LA: Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol. Pathol. (2003) 31:638-645.
   Google Scholar
• LOSCO PE, EVANS EW, BARAT SA et al.: The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol. Pathol. (2004) 32:295-308.
   Google Scholar
• LARSON JL, PINO MV, GEIGER LE, SIMEONE CR: The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. (1996) 78:44-49.
   Web of Science ®Google Scholar
• BIAN H, ZHANG J, WU P et al.: Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem. Pharmacol. (2004) 68:2229-2236.
   Google Scholar
• SILVESTRE J, GRAUL A, CASTANER J: SB-207499. Antiasthmatic/anti- inflammatory phosphodiesterase IV inhibitor. Drugs Fut. (1998) 23:607-615.
   Google Scholar
• NIEMAN RB, FISHER BD, AMIT O, DOCKHORN RJ: SB 207499 (Ariflo), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. (1998) 15:A413.
   Web of Science ®Google Scholar
• SEALE JP: IDDB meeting report. European Respiratory Society Annual Congress, Madrid, Spain (9 – 13 October 1999).
   Google Scholar
• COMPTON C, GUBB J, CEDAR E et al.: Ariflo (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD. Am. J. Respir. Crit. Care Med. (1999) 159:A522.
   Google Scholar
• GIEMBYCZ MA: An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. (2006) 62:138-152.
   Web of Science ®Google Scholar
• RENNARD SI, SCHACHTER N, STREK M, RICKARD K, AMIT O: Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest (2006) 129:56-66.
   PubMed Web of Science ®Google Scholar
• BAGCHI I, BAKST JE, EDELSON JE, AMIT O: Cilomast reduces healthcare resource utilization of chronic obstuctive pulmonary disease patients. Abs. Am. Thorac Soc. (2001):716 (Poster).
   Google Scholar
• LIM S, ZHU J, LAKE P: Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD. Eur. Respir. J. (2004) 24(Suppl. 48):P648.
   Google Scholar
• RAM FS, JARDIN JR, ATALLAH A et al.: Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir. Med. (2005) 99:135-144.
   Google Scholar
• TAUBE C, KANNIESS F, GRONKE L et al.: Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma. Respir. Med. (2003) 97:568-577.
   Google Scholar
• JONES PW, QUIRK FH, BAVEYSTOCK CM, LITTLEJOHNS P: A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis. (1992) 145:1321-1327.
   Web of Science ®Google Scholar
• BLAND JM, ALTMAN DG: Some examples of regression towards the mean. Br. Med. J. (1994) 309:780.
   PubMed Web of Science ®Google Scholar
• BLAND JM, ALTMAN DG: Regression towards the mean. Br. Med. J. (1994) 308:1499.
   PubMed Web of Science ®Google Scholar
• CALVERLEY PMA, BURGE PS, SPENCER S, ANDERSON JA, JONES PW FOR THE ISOLDE STUDY INVESTIGATORS: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax (2003) 58:659-664.
   PubMed Web of Science ®Google Scholar
• CELLI B: COPD, inflammation an ist modulation by phosphodiesterase 4 inhibitors. Time to look beyond the FEV1. Chest (2006) 129:5-6.
   PubMed Web of Science ®Google Scholar
• RABE KF, BATEMAN ED, O’DONNELL D, WITTE S, BREDENBROKER D, BETHKE TD: Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2005) 366(9485):563-571.
   PubMed Web of Science ®Google Scholar
• SIN DD, McALISTER FA, MAN SF, ANTHONISEN NR: Contemporary management of chronic obstructive pulmonary disease: scientific review. J. Am. Med. Assoc. (2003) 290:2301-2312.
   PubMed Web of Science ®Google Scholar
• RAM FS, JONES PW, CASTRO AA et al.: Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2002) 4:CD003902.
   PubMedGoogle Scholar
• WANG P, WU P, OHLETH KM, EGAN RW, BILLAH MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. (1999) 56:170-174.
   Google Scholar
• OBERNOLTE R, RATZLIFF J, BAECKER PA et al.: Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochim. Biophys. Acta (1997) 1353:287-297.
   Google Scholar
• ERDOGAN S, HOUSLAY MD: Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Bio. Chem. J. (1997) 321:165-175.
   PubMed Web of Science ®Google Scholar
• FDC: Ariflo COPD long-term efficacy studies should use active controls - Cmte. FDC Reports Pink Sheet (2003):65 37 22.
   Google Scholar